文献速递肝胆胰外科围术期管理与 ERAS

不可逆电穿孔治疗局部晚期胰腺癌不良事件的多机构综述

Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer.
PubMed 文献 · Surgery · 2023-10-16

该多机构前瞻性数据库综述分析了2015年12月至2022年3月接受不可逆电穿孔治疗的201例局部晚期胰腺腺癌患者的不良事件,并与200例接受胰腺切除术的腺癌患者对照。不可逆电穿孔组不良事件发生率为25%,显著低于胰腺切除术组的39%(P=0.004);不可逆电穿孔组最常见的并发症为感染(13例)、消化道出血(11例)和腹水(7例)。多因素分析显示,接受高剂量新辅助放疗、电极包绕肠系膜上动脉/肠系膜上静脉/门静脉以及胆管支架留置超过6个月的患者发生严重(≥3级)不良事件的风险增加。

要点

  • 不可逆电穿孔组不良事件发生率为25%,显著低于胰腺切除术组的39%(P=0.004)。
  • 不可逆电穿孔组最常见的并发症为感染(13例)、消化道出血(11例)和腹水(7例)。
  • 高剂量新辅助放疗、电极包绕肠系膜上动脉/肠系膜上静脉/门静脉及胆管支架留置超过6个月与严重不良事件风险增加相关。

核心结论

  • 本研究显示局部晚期胰腺腺癌接受不可逆电穿孔治疗的不良事件发生率为25%,显著低于早期疾病接受胰腺切除术的39%(P=0.004)。
  • 不可逆电穿孔组存在某些独特的不良事件,在治疗这些患者时应予以理解。

研究设计与样本

  • 研究为多机构前瞻性数据库综述,纳入2015年12月至2022年3月接受不可逆电穿孔治疗的201例局部晚期胰腺腺癌患者。
  • 对照组为200例接受胰腺切除术的胰腺腺癌患者。

主要发现

  • 不可逆电穿孔组201例中51例发生不良事件,胰腺切除术组200例中78例发生不良事件。
  • 不可逆电穿孔组在3C期患者中术后腹水发生率显著更高。
  • 不可逆电穿孔组最常见的并发症为感染(n=13)、消化道出血(n=11)和腹水(n=7)。
  • 多因素分析显示,接受高剂量新辅助放疗的不可逆电穿孔患者发生严重(≥3级)不良事件的风险增加(风险比2.4;95%置信区间1.4-5.4)。
  • 多因素分析显示,不可逆电穿孔电极包绕肠系膜上动脉、肠系膜上静脉和门静脉的患者发生严重(≥3级)不良事件的风险增加(风险比1.9;95%置信区间1.3-3.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Irreversible electroporation is a novel approach for treating locally advanced pancreatic adenocarcinoma. However, this ablative technique is not without risk and has the potential to precipitate adverse events. The aim of this study was to delineate risk factors that increase this risk, as well as to elucidate the risk profile associated with irreversible electroporation in the setting of locally advanced pancreatic adenocarcinoma. METHODS: A review of our prospective multi-institutional database from December 2015 to March 2022 of patients with locally advanced pancreatic adenocarcinoma who underwent irreversible electroporation was analyzed for adverse events. These were then compared with a control population of patients undergoing pancreatectomy for adenocarcinoma. RESULTS: Adverse events occurred in 51 patients of the 201 patients treated with irreversible electroporation compared with 78 of the 200 patients treated with pancreatectomy. The irreversible electroporation group had a significantly greater incidence of postoperative ascites in stage 3C patients. The most common complications in the irreversible electroporation group were infectious (n = 13), gastrointestinal bleed (n = 11), and ascites (n = 7). Multivariate analysis demonstrated increased risk of severe (grade ≥3) adverse events in the irreversible electroporation cohort who received high dose, neoadjuvant radiation (hazard ratio, 2.4; 95% confidence interval, 1.4-5.4), irreversible electroporation electrodes bracketing the superior mesenteric artery, superior mesenteric vein, and portal venous vein (hazard ratio, 1.9; 95% confidence interval, 1.3-3.4), and who had a bile duct stent in place for >6 months (hazard ratio, 1.7; 95% confidence interval, 1.2-5.6). There were similar rates of 90-day mortality in both groups, irreversible electroporation 2.4% vs pancreatectomy 2.8%. CONCLUSION: This study revealed a 25% rate of adverse events associated with irreversible electroporation in locally advanced pancreatic adenocarcinoma, which was significantly less (P = .004) than the 39% rate of adverse events associated with pancreatectomy in early-stage disease. Certain unique adverse events in the irreversible electroporation group have been established and should be understood in the care of these patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Stephens K, Philips PP, Egger ME, et al. Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer. Surgery. 2023. PMID: 37852831. doi:10.1016/j.surg.2023.08.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。